Voyager Therapeutics price to free cash flow VYGR

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 54.8×; Aug 2024
7-year median: 12.5×
7-year range: 3.1× to 286×
Peer median: 20.6×

Voyager Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2024, at 54.8×.

On the days it had one over the last 7 years, its median was 12.5×, from 3.1× in Oct 2023 to 286× in Jul 2022.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	54.8×	3.8×	61.2×
2023	4.3×	3.1×	46.1×
2022	26.1×	23.1×	286×
2021	n/m a value too high to mean anything
2020	9.6×	6.3×	12.5×
2019	12.1×	11.1×	18.0×

Against its peers

Companies in Healthcare nearest Voyager Therapeutics' size, closest first, today.

Company	Price to free cash flow
VYGRVoyager Therapeutics	n/m
KEQUKewaunee Scientific	8.7×
ICCCImmucell	22.1×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
PDEXPro DEX	29.5×
APTAlpha Pro Tech	9.7×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
ELMDElectromed	26.2×
UTMDUtah Medical Products	20.6×
Peer median	20.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Voyager Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.